Lista de obras - Timothy Hughes - Dominio Público Uruguay

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

artículo científico publicado en 2014

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

artículo científico publicado en 2013

A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response.

artículo científico publicado en 2009

Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7q34-35, a region frequently affected in haematological neoplasms

artículo científico publicado en 1995

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance

artículo científico publicado en 2013

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

artículo científico publicado en 2015

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

artículo científico publicado en 2010

Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity

artículo científico publicado en 2010

Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia

artículo científico publicado en 2020

Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells

artículo científico publicado en 2012

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

artículo científico publicado en 2008

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

artículo científico publicado en 2008

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.

artículo científico publicado en 2009

Detection of minimal residual disease in an AML patient with trisomy 8 using interphase FISH

artículo científico publicado en 1997

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

artículo científico publicado en 2012

Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients

artículo científico publicado en 2013

Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

scholarly article published in Leukemia

Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

scholarly article published in Leukemia

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

artículo científico publicado en 2020

False-positive results with PCR to detect leukaemia-specific transcript.

artículo científico publicado en 1990

High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse

artículo científico publicado en 2020

Imatinib mesylate causes growth plate closure in vivo.

artículo científico publicado en 2009

Improved results with PCR for chronic myeloid leukaemia

artículo científico publicado en 1990

In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy

scientific article published on 02 January 2021

Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.

artículo científico

Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia

artículo científico publicado en 2004

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

artículo científico publicado en 2008

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

scientific article published on 27 March 2019

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

artículo científico publicado en 2016

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

artículo científico publicado en 2021

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st

artículo científico publicado en 2014

Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation

artículo científico publicado en 2013

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials

artículo científico publicado en 2015

Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination.

artículo científico publicado en 2014

Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex vivo and in vivo T-cell depletion.

artículo científico publicado en 1993

Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

artículo científico publicado en 1999

Mutational analysis in chronic myeloid leukemia: when and what to do? ⬇️

artículo científico publicado el 1 de marzo de 2011

NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis

artículo científico publicado en 2012

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells

artículo científico publicado en 2010

Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.

artículo científico publicado en 2017

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

artículo científico publicado en 2012

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

artículo científico publicado en 2010

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

artículo científico publicado en 2012

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

artículo científico publicado en 2009

OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.

artículo científico publicado en 2010

OCT-1 as a determinant of response to antileukemic treatment.

artículo científico publicado en 2011

OCT1 and imatinib transport in CML: is it clinically relevant?

artículo científico

Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia

artículo científico publicado en 1997

Polymerase chain reaction for detection of residual leukaemia

artículo científico publicado en 1989

Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells

artículo científico publicado en 2015

Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.

artículo científico publicado en 2011

Practical Considerations for Monitoring Patients With Chronic Myeloid Leukemia ⬇️

artículo científico publicado el 1 de octubre de 2010

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.

artículo científico publicado en 2012

Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells.

artículo científico publicado en 2012

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia

artículo científico publicado en 2016

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.

artículo científico publicado en 2014

Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?'

artículo científico publicado en 2016

Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning

artículo científico publicado en 1992

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells

artículo científico publicado en 2009

Significance of residual leukaemia transcripts after bone marrow transplant for CML

artículo científico publicado en 1990

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

artículo científico publicado en 2009

Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow

artículo científico publicado en 1989

Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells

scientific article published on 30 April 2020

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

artículo científico publicado en 2017

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia

artículo científico publicado en 2014

TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries

scientific article published on 30 March 2020

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

artículo científico publicado en 2016

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment

artículo científico publicado en 2016

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.

artículo científico publicado en 2008

There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge

scientific article published on 10 November 2020

Lista de obras de Timothy Hughes

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response.

Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7q34-35, a region frequently affected in haematological neoplasms

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity

Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia

Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.

Detection of minimal residual disease in an AML patient with trisomy 8 using interphase FISH

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

Elevated PTPN2 expression is associated with inferior molecular response in de-novo chronic myeloid leukaemia patients

Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

False-positive results with PCR to detect leukaemia-specific transcript.

High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse

Imatinib mesylate causes growth plate closure in vivo.

Improved results with PCR for chronic myeloid leukaemia

In-vitro modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene RANBP2-ABL1 - implications for targeted therapy

Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.

Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st

Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials

Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination.

Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex vivo and in vivo T-cell depletion.

Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics

Mutational analysis in chronic myeloid leukemia: when and what to do? ⬇️

NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis

Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells

Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd.

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.

OCT-1 as a determinant of response to antileukemic treatment.

OCT1 and imatinib transport in CML: is it clinically relevant?

Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia

Polymerase chain reaction for detection of residual leukaemia

Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells

Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.

Practical Considerations for Monitoring Patients With Chronic Myeloid Leukemia ⬇️

Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.

Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells.

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia

Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment.

Response to 'Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?'

Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells

Significance of residual leukaemia transcripts after bone marrow transplant for CML

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow

Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia

TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy.

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment

Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.

There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge